Veracyte Inc
Suletud
SektorTervishoid
47.27 -0.34
Ülevaade
Aktsiahinna muutus
24h
Min
46.45
Max
47.35
Sissetulek | -20M 29M |
|---|---|
Müük | -1.6M 139M |
P/E Sektori keskmine | 45.019 49.052 |
Aktsiakasum | 0.52 |
Kasumimarginaal | 20.642 |
Töötajad | 755 |
EBITDA | -17M 29M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +0.51% upside |
Järgmine tulemuste avaldamine | 5. aug 2026 |
|---|
Turukapital | 1.1B 3.8B |
|---|---|
Eelmine avamishind | 47.61 |
Eelmine sulgemishind | 47.27 |
Uudiste sentiment
By Acuity
50%
50%
146 / 342 Pingereas Healthcare
Veracyte Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.